Matrix metalloproteinase 11 (MMP11) has been shown to play a key role in human tumor progression and indicates poor clinical outcome in cancer patients.
OBJECTIVE:
The current study aimed to evaluate the relationship between serum levels of MMP-11 and prognosis in colon cancer patients.
METHODS:
Serum levels of MMP-11 were determined in 92 colon cancer patients and 92 healthy individuals using an enzyme-linked immunosorbent assay (ELISA). Associations between serum MMP-11 levels and clinicopathological characteristics of the patients and their outcomes were investigated. Survival analyses were performed to measure the 5-year overall survival (OS) and disease-free survival (DFS).
RESULTS:
Serum MMP-11 levels were substantially higher in colon cancer patients than in healthy controls. Moreover, serum MMP-11 levels were significantly higher in patients with advanced T status, lymph node metastasis, distant metastasis, and a higher TNM stage. Elevated serum levels of MMP-11 were identified as an independent prognostic factor for 5-year mortality and adverse events associated with colon cancer. Multivariate Cox regression analysis identified the serum MMP-11 level as an independent predictor of OS and DFS.
CONCLUSION:
Our study established that high serum levels of MMP-11 are associated with poor clinical outcome and may serve as a prognostic biomarker in colon cancer patients.
AndarawewaK.L., BoulayA., MassonW., MathelinC., StollI., TomasettoC., ChenardM.P., GintzM., BellocqJ.P. and RioM.C., Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression, Cancer Research63 (2003), 5844-5849.
2.
BartolomeR.A., FerreiroS., Miquilena-ColinaM.E., Martinez-PratsL., Soto-MontenegroM.L., Garcia-BernalD., VaqueroJ.J., AgamiR., DelgadoR., DescoM., Sanchez-MateosP. and TeixidoJ., The Chemokine Receptor CXCR4 and the Metalloproteinase MT1-MMP Are Mutually Required during Melanoma Metastasis to Lungs, American Journal of Pathology174 (2009), 602-612.
3.
BoulayA., MassonR., ChenardM.P., El FahimeM., CassardL., BellocqJ.P., Sautes-FridmanC., BassetP. and RioM.C., High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase, Cancer Research61 (2001), 2189-2193.
4.
DelebecqT.J., PorteH., ZerimechF., CopinM.C., GouyerV., DacquembronneE., BalduyckM., WurtzA. and HuetG., Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer, Clinical Cancer Research6 (2000), 1086-1092.
5.
DengH., GuoR.F., LiW.M., ZhaoM. and LuY.Y., Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells, Biochemical and Biophysical Research Communications326 (2005), 274-281.
6.
DuffyM.J., MaguireT.M., HillA., McDermottE. and O'HigginsN., Metalloproteinases: role in breast carcinogenesis, invasion and metastasis, Breast Cancer Research2 (2000), 252-257.
7.
EdgeS.B. and ComptonC.C., The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM, Annals of Surgical Oncology17 (2010), 1471-1474.
8.
EscaffS., FernandezJ.M., GonzalezL.O., SuarezA., Gonzalez-ReyesS., GonzalezJ.M. and VizosoF.J., Study of matrix metalloproteinases and their inhibitors in prostate cancer, British Journal of Cancer102 (2010), 922-929.
9.
HsinC.-H., ChenM.-K., TangC.-H., LinH.-P., ChouM.-Y., LinC.-W. and YangS.-F., High Level of Plasma Matrix Metalloproteinase-11 Is Associated with Clinicopathological Characteristics in Patients with Oral Squamous Cell Carcinoma, Plos One9 (2014), e113129.
10.
JemalA., BrayF., CenterM.M., FerlayJ., WardE. and FormanD., Global Cancer Statistics, Ca-a Cancer Journal for Clinicians61 (2011), 69-90.
11.
JiaL., WangS., CaoJ., ZhouH., WeiW. and ZhangJ., siRNA targeted against matrix metalloproteinase 11 inhibits the metastatic capability of murine hepatocarcinoma cell Hca-F to lymph nodes, International Journal of Biochemistry & Cell Biology39 (2007), 2049-2062.
12.
KrenL., GoncharukV.N., KrenovaZ., StratilD., HermanovaM., SkrickovaJ., SheehanC.E. and RossJ.S., Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies, Ceskoslovenska patologie42 (2006), 16-9.
13.
MinK.-W., KimD.-H., DoS.-I., PyoJ.-S., KimK., ChaeS.W., SohnJ.H., OhY.-H., KimH.J., ChoiS.H., ChoiY.J. and ParkC.H., Diagnostic and Prognostic Relevance of MMP-11 Expression in the Stromal Fibroblast-Like Cells Adjacent to Invasive Ductal Carcinoma of the Breast, Annals of Surgical Oncology20 (2013), S433-S442.
14.
MossL.A.S., Jensen-TaubmanS. and Stetler-StevensonW.G., Matrix Metalloproteinases Changing Roles in Tumor Progression and Metastasis, American Journal of Pathology181 (2012), 1895-1899.
15.
NonsrijunN., MitchaiJ., BrownK., LeksomboonR. and TuamsukP., Overexpression of Matrix Metalloproteinase 11 in Thai Prostatic Adenocarcinoma is Associated with Poor Survival, Asian Pacific Journal of Cancer Prevention14 (2013), 3331-3335.
16.
PedersenG., SaermarkT., KirkegaardT. and BrynskovJ., Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium, Clinical and Experimental Immunology155 (2009), 257-265.
17.
PorteH., ChastreE., PrevotS., NordlingerB., EmpereurS., BassetP., ChambonP. and GespachC., Neoplastic progression of human colorectal-cancer is associated with overexpression of the stromelysin-3 AND BM-40/Sparc genes, International Journal of Cancer64 (1995), 70-75.
18.
RoscilliG., CappellettiM., De VitisC., CilibertoG., Di NapoliA., RucoL., ManciniR. and AurisicchioL., Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients, Journal of Translational Medicine12 (2014), 54.
19.
SoniS., MathurM., ShuklaN.K., DeoS.V.S. and RalfhanR., Stromelysin-3 expression is an early event in human oral tumorigenesis, International Journal of Cancer107 (2003), 309-316.
20.
StojicJ., HagemannC., HaasS., HerboldC., KuehnelS., GerngrasS., RoggendorfW., RoosenK. and VinceG.H., Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas, Neuroscience Research60 (2008), 40-49.
21.
TejparS., BertagnolliM., BosmanF., LenzH.-J., GarrawayL., WaldmanF., WarrenR., BildA., Collins-BrennanD., HahnH., HarkinD.P., KennedyR., IlyasM., MorreauH., ProutskiV., SwantonC., TomlinsonI., DelorenziM., FioccaR., Van CutsemE. and RothA., Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery, Oncologist15 (2010), 390-404.
22.
ThewesM., PohlmannG., AtkinsonM., MuellerJ., PutzB. and HoflerH., Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas - Localization and clinicopathologic correlations, Diagnostic Molecular Pathology5 (1996), 284-290.
23.
ThornsV., WalterG.F. and ThornsC., Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas, Anticancer Research23 (2003), 3937-3944.
24.
Vazquez-OrtizG., Pina-SanchezP., VazquezK., DuenasA., TajaL., MendozaP., GarciaJ.A. and SalcedoM., Overexpression of cathepsin f, matrix metalloproteinases 11 and 12 in cervical cancer, Bmc Cancer5 (2005), 68.
25.
WaseniusV.M., HemmerS., KettunenE., KnuutilaS., FranssilaK. and JoensuuH., Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: A cDNA and tissue microarray study, Clinical Cancer Research9 (2003), 68-75.
YanD., DaiH. and LiuJ.-W., Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma, Bmc Cancer11 (2011), 165.
28.
ZhaoZ.-S., ChuY.-Q., YeZ.-Y., WangY.-Y. and TaoH.-Q., Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance, Human Pathology41 (2010), 686-696.
